" /> Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4 /CD8 Central Memory T-lymphocytes JCAR014 - CISMeF





Preferred Label : Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4 /CD8 Central Memory T-lymphocytes JCAR014;

NCIt synonyms : Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4 /CD8 CM T-lymphocytes JCAR014;

NCIt definition : A defined preparation of CD4 and CD8 central memory (CM) autologous T-lymphocytes transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) containing an anti-CD19 single chain variable fragment (scFv) fused to the signaling domains of CD28, 4-1BB (CD137), the zeta chain of the TCR/CD3 complex (CD3-zeta), and a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, autologous anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4 /CD8 CM T-lymphocytes JCAR014 are directed to and induce selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. Devoid of both ligand binding domains and tyrosine kinase activity, the expressed EGFRt both facilitates in vivo detection of the administered, transduced T-cells and can promote elimination of those cells through a cetuximab-induced antibody dependent cellular cytotoxicity (ADCC) response. The 4-1BB costimulatory signaling domain enhances both proliferation of T-cells and antitumor activity.;

Molecule name : JCAR014;

NCI Metathesaurus CUI : CL505072;

Details


Keyword's position in hierarchy(ies) : arborescence

You can consult :


Nous contacter.
12/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.